论文部分内容阅读
目的比较多西他赛单药、顺铂单药以及两药联合三种方案治疗晚期非小细胞肺癌(NSCLC)的疗效。方法 104例经病理确诊无手术指征的晚期NSCLC患者。多西他赛组给予艾素75 mg/m2,顺铂组给予顺铂100 mg/m2,联合组给予艾素75 mg/m2加顺铂80 mg/m2。比较三个化疗方案反应率、中位生存期、1 a生存率。结果联合组的反应率和中位生存期明显高于其他两组。结论多西他赛联合顺铂有较好疗效,单用顺铂不能延长患者的生存期。
Objective To compare the efficacy of docetaxel alone, cisplatin alone and two regimens in the treatment of advanced non-small cell lung cancer (NSCLC). Methods One hundred and four patients with advanced non-small cell lung cancer (NSCLC) who were pathologically confirmed without surgery were enrolled. The docetaxel group received 75 mg / m2 of aldosteron, cisplatin 100 mg / m2 in the cisplatin group, and 80 mg / m2 cisplatin in the combination group. Three chemotherapy regimens were compared for response rate, median survival, and 1-year survival. Results The response rate and median survival in the combined group were significantly higher than those in the other two groups. Conclusion Docetaxel combined with cisplatin has a good effect, with cisplatin alone can not extend the survival of patients.